Left Ventricular or Biventricular Pacing Improves Cardiac Function at Diminished Energy Cost in Patients With Dilated Cardiomyopathy and Left Bundle-Branch Block

Background—Left ventricular or biventricular pacing/stimulation can acutely improve systolic function in patients with dilated cardiomyopathy (DCM) and intraventricular conduction delay by resynchronizing contraction. Most heart failure therapies directly enhancing systolic function do so while concomitantly increasing myocardial oxygen consumption (MVO2). We hypothesized that pacing/stimulation, in contrast, incurs systolic benefits without raising energy demand. Methods and Results—Ten DCM patients with left bundle-branch block (ejection fraction 20±3%, QRS duration179±3 ms, mean±SEM) underwent cardiac catheterization to measure ventricular and aortic pressure, coronary blood flow, arterial–coronary sinus oxygen difference (&Dgr;AVO2), and M&OV0312;O2. Data were measured under sinus rhythm or with left ventricular or biventricular pacing/stimulation at the same heart rate. These results were then contrasted to intravenous dobutamine (n=7) titrated to match systolic changes during LV pacing. Systolic function rose quickly and substantially from LV pacing (18±4% rise in arterial pulse pressure, which correlates with cardiac output, and 43±6% increase in dP/dtmax; both P <0.01). However, &Dgr;AVO2 and M&OV0312;O2 declined −4±2% and −8±6.5%, respectively (both P <0.05). Similar results were obtained with biventricular activation. In contrast, dobutamine raised dP/dtmax 37±6%, accompanied by a 22±11% rise in per-beat M&OV0312;O2 (P <0.05 versus pacing). Conclusions—Ventricular resynchronization by left ventricular or biventricular pacing/stimulation in DCM patients with left bundle-branch block acutely enhances systolic function while modestly lowering energy cost. This should prove valuable for treating DCM patients with basal dyssynchrony.

[1]  Andrew P. Kramer,et al.  Predictors of systolic augmentation from left ventricular preexcitation in patients with dilated cardiomyopathy and intraventricular conduction delay. , 2000, Circulation.

[2]  D. Sawyer,et al.  Mitochondrial oxidative stress in heart failure: "oxygen wastage" revisited. , 2000, Circulation research.

[3]  J. Willerson Circulation's first 50 years: January 1950 to January 2000. , 2000, Circulation.

[4]  D. Kass,et al.  Mechanical dyssynchrony in dilated cardiomyopathy with intraventricular conduction delay as depicted by 3D tagged magnetic resonance imaging. , 2000, Circulation.

[5]  C. H. Chen,et al.  Comparison of ventricular pressure relaxation assessments in human heart failure: quantitative influence on load and drug sensitivity analysis. , 1999, Journal of the American College of Cardiology.

[6]  J. Hoerter,et al.  Subcellular creatine kinase alterations. Implications in heart failure. , 1999, Circulation research.

[7]  R. Califf,et al.  Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). , 1999, American heart journal.

[8]  AngeloAuricchio,et al.  Effect of Pacing Chamber and Atrioventricular Delay on Acute Systolic Function of Paced Patients With Congestive Heart Failure , 1999 .

[9]  F W Prinzen,et al.  Mapping of regional myocardial strain and work during ventricular pacing: experimental study using magnetic resonance imaging tagging. , 1999, Journal of the American College of Cardiology.

[10]  C. H. Chen,et al.  Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. , 1999, Circulation.

[11]  E. Daoud,et al.  Biventricular pacing in patients with congestive heart failure: two prospective randomized trials. The VIGOR CHF and VENTAK CHF Investigators. , 1999, The American journal of cardiology.

[12]  E. McVeigh,et al.  Mapping propagation of mechanical activation in the paced heart with MRI tagging. , 1999, American journal of physiology. Heart and circulatory physiology.

[13]  L. La Vecchia,et al.  Left ventricular versus biventricular dysfunction in idiopathic dilated cardiomyopathy. , 1999, The American journal of cardiology.

[14]  H Le Breton,et al.  Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure. , 1998, Journal of the American College of Cardiology.

[15]  J. Ingwall,et al.  Nitric oxide, myocardial oxygen consumption, and ATP synthesis. , 1998, Circulation research.

[16]  F. Recchia,et al.  Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. , 1998, Circulation research.

[17]  P. Poole‐Wilson,et al.  Successes and failures of current treatment of heart failure , 1998, The Lancet.

[18]  W. Colucci,et al.  New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress , 1998, The Lancet.

[19]  B. Massie 15 years of heart-failure trials: what have we learned? , 1998, The Lancet.

[20]  J. Blanc,et al.  Evaluation of different ventricular pacing sites in patients with severe heart failure: results of an acute hemodynamic study. , 1997, Circulation.

[21]  C. Brohet,et al.  Dispersion of ventricular repolarization in dilated cardiomyopathy. , 1997, European heart journal.

[22]  A. Katz Is the failing heart an energy-starved organ? , 1996, Journal of cardiac failure.

[23]  A. Lazarus,et al.  Multisite Pacing for End‐Stage Heart Failure: Early Experience , 1996, Pacing and clinical electrophysiology : PACE.

[24]  D. Burkhoff,et al.  Effects of levosimendan on myocardial contractility and oxygen consumption. , 1996, The Journal of pharmacology and experimental therapeutics.

[25]  M. Packer New concepts in the pathophysiology of heart failure: beneficial and deleterious interaction of endogenous haemodynamic and neurohormonal mechanisms , 1996, Journal of internal medicine.

[26]  D. Gibson,et al.  Natural history of abnormal conduction and its relation to prognosis in patients with dilated cardiomyopathy. , 1996, International journal of cardiology.

[27]  H. Suga,et al.  Logistic time constant of isovolumic relaxation pressure-time curve in the canine left ventricle. Better alternative to exponential time constant. , 1995, Circulation.

[28]  P. Grayburn,et al.  Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. , 1994, Journal of the American College of Cardiology.

[29]  W. Remme,et al.  Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure. , 1994, Journal of cardiovascular pharmacology.

[30]  N. Alpert,et al.  Positive inotropism and myocardial energetics: influence of beta receptor agonist stimulation, phosphodiesterase inhibition, and ouabain. , 1994, Cardiovascular research.

[31]  M. Schwaiger,et al.  Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy. , 1993, Journal of the American College of Cardiology.

[32]  P. Wilmshurst Why inotropes continue to disappoint in heart failure. , 1993, British heart journal.

[33]  C. Richard,et al.  Cardiac index vs oxygen-derived parameters for rational use of dobutamine in patients with congestive heart failure. , 1993, Chest.

[34]  G. Critelli,et al.  Resting and ambulatory ECG predictors of mode of death in dilated cardiomyopathy. , 1992, Journal of electrocardiology.

[35]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[36]  P. Grayburn,et al.  Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. , 1990, Circulation.

[37]  R D Fish,et al.  Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. , 1990, Circulation.

[38]  H Suga,et al.  Ventricular energetics. , 1990, Physiological reviews.

[39]  T. Meinertz,et al.  Myocardial energetics in patients with dilated cardiomyopathy. Influence of nitroprusside and enoximone. , 1989, Circulation.

[40]  T. Meinertz,et al.  Influence of Enoximone on Myocardial Energetics in Patients with Idiopathic Dilated Cardiomyopathy: Comparison with Nitroprusside , 1989, Journal of cardiovascular pharmacology.

[41]  H. F. Marlow The Efficacy of Xamoterol in Heart Failure of Ischemic Origin , 1989, Journal of cardiovascular pharmacology.

[42]  R. Huth,et al.  Acute Hemodynamic Response to Intravenous Enoximone: An Animal Study and Preliminary Report in Infants After Cardiac Surgery , 1989, Journal of cardiovascular pharmacology.

[43]  K. Sagawa,et al.  Influence of pacing site on canine left ventricular contraction. , 1986, The American journal of physiology.

[44]  E. Braunwald,et al.  Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. , 1986, Circulation.

[45]  R. O'rourke,et al.  Effect of alteration of left ventricular activation sequence on the left ventricular end-systolic pressure-volume relation in closed-chest dogs. , 1985, Circulation research.

[46]  B. Pitt,et al.  Coronary Hemodynamic Effects of Increasing Ventricular Rate in the Unanesthetized Dog , 1968, Circulation research.